<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02238314</url>
  </required_header>
  <id_info>
    <org_study_id>1182.2</org_study_id>
    <nct_id>NCT02238314</nct_id>
  </id_info>
  <brief_title>Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients</brief_title>
  <official_title>Tipranavir Disodium: An Open-Label ExploratorySstudy of Tipranavir and Ritonavir in Combination With One Nucleoside Reverse Transcriptase Inhibitor and One Non-Nucleoside Reverse Transcriptase Inhibitor in Multiple Protease Inhibitor-Experienced HIV Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective was to evaluate the antiviral activity and safety of two regimens of&#xD;
      tipranavir (500 mg BID or 1000 mg BID) plus ritonavir (100 mg BID) administered in&#xD;
      combination with 1 new nucleoside reverse transcriptase inhibitor (NRTI) + efavirenz in&#xD;
      multiple protease-inhibitor-experienced HIV-1 positive patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <primary_completion_date type="Actual">August 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HIV-1 RNA concentrations</measure>
    <time_frame>weeks 16, 24, 48 and 80</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of HIV-1 RNA levels below the limit of quantitation (BLQ) (400 copies/mL)</measure>
    <time_frame>up to 112 weeks</time_frame>
    <description>measured by the Roche Amplicor HIV-1 Monitor™ polymerase chain reaction (PCR) Method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of HIV-1 RNA levels BLQ (50 copies/mL)</measure>
    <time_frame>up to 112 weeks</time_frame>
    <description>measured by the Roche Amplicor UltraSensitive™ PCR Method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with treatment-emergent and drug-related adverse events (AEs)</measure>
    <time_frame>up to 115 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with serious adverse events (SAEs)</measure>
    <time_frame>up to 115 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with grade 3 and 4 laboratory abnormalities</measure>
    <time_frame>up to 115 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cluster of differentiation (CD) 4+ cell count responses</measure>
    <time_frame>weeks 24, 48 and 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD8+ cell count responses</measure>
    <time_frame>weeks 24, 48 and 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to new or recurring AIDS-defining illness</measure>
    <time_frame>up to 115 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to new or recurring HIV-related illness</measure>
    <time_frame>up to 115 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>up to 115 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of AIDS-defining illness,</measure>
    <time_frame>up to 115 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of HIV-related illness,</measure>
    <time_frame>up to 115 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of death</measure>
    <time_frame>up to 115 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virologic failure</measure>
    <time_frame>up to 115 weeks</time_frame>
    <description>defined as plasma HIV-1 RNA values &gt;400 copies/mL or a 0.5 log reduction from baseline at two consecutive time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cholesterol</measure>
    <time_frame>up to 115 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HDL</measure>
    <time_frame>up to 115 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in triglycerides</measure>
    <time_frame>up to 115 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood glucose</measure>
    <time_frame>up to 115 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state plasma concentrations</measure>
    <time_frame>up to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold-change in concentration required to produce 50% of inhibition (IC 50)</measure>
    <time_frame>Baseline, weeks 24, 48 and 80</time_frame>
    <description>sequence-based HIV-1 analysis (genotyping) and drugs susceptibility assays (phenotyping)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Tipranavir low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tipranavir high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir low dose</intervention_name>
    <arm_group_label>Tipranavir low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir high dose</intervention_name>
    <arm_group_label>Tipranavir high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>Tipranavir high dose</arm_group_label>
    <arm_group_label>Tipranavir low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleoside Reverse Transcriptase Inhibitor (NRTI)</intervention_name>
    <arm_group_label>Tipranavir high dose</arm_group_label>
    <arm_group_label>Tipranavir low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)</intervention_name>
    <arm_group_label>Tipranavir high dose</arm_group_label>
    <arm_group_label>Tipranavir low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Multiple (two or more) PI-experience. Eligible patients must have had exposure to at&#xD;
             least two antiretroviral regimens containing a single protease inhibitor or a regimen&#xD;
             containing dual protease inhibitors&#xD;
&#xD;
          -  In the investigator's opinion, the patient had adhered to PI-containing regimens&#xD;
&#xD;
          -  Exposure of ≥ 3 months to the current PI therapy&#xD;
&#xD;
          -  Exposure of ≥ 4 months to the prior PI therapy with single PI-containing regimens&#xD;
&#xD;
          -  Stable PI-containing regimen for at least 2 months prior to study entry&#xD;
&#xD;
          -  HIV-1-RNA ≥ 5,000 copies/mL&#xD;
&#xD;
          -  Cluster of differentiation (CD)4+ cell count ≥ 50 cells/mm**3&#xD;
&#xD;
          -  At least one new NRTI option available&#xD;
&#xD;
          -  Age ≥ 13 years&#xD;
&#xD;
          -  Acceptable screening laboratory values that indicated adequate baseline organ function&#xD;
             at the time of screening. Laboratory values were considered acceptable if the severity&#xD;
             was ≤ Grade 1 (AIDS Clinical Trial Group (ACTG) Grading Scale). Stable Grade 2&#xD;
             abnormalities were permitted if the values had been demonstrated and documented for at&#xD;
             least ≥ 2 months.&#xD;
&#xD;
          -  Acceptable medical history, physical examination, electrocardiogram, and chest X-ray&#xD;
             prior to entry into the treatment phase of the study&#xD;
&#xD;
          -  Agreement to use a barrier contraceptive method of birth control for at least 30 days&#xD;
             prior to study drug administration, during the study, and 30 days after the end of the&#xD;
             study&#xD;
&#xD;
          -  Ability to swallow numerous tablets and capsules without difficulty&#xD;
&#xD;
          -  Ability to understand and provide informed consent. Minors were required to have&#xD;
             approval of a parent or legal guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure, defined as &gt; 7 treatment days, to nonnucleoside reverse transcriptase&#xD;
             inhibitor (NNRTIs) including, but not limited to: nevirapine, efavirenz, delavirdine,&#xD;
             atevirdine, MKC-442, loviride, and HBY-097&#xD;
&#xD;
          -  Clinically significant active or acute (onset within the month previous to study&#xD;
             entry) medical problems, including the following: opportunistic infections, such as&#xD;
             active cryptococcosis, Pneumocystis carinii pneumonia, herpes zoster, histoplasmosis,&#xD;
             or cytomegalovirus or nonopportunistic diseases, including, but not limited to,&#xD;
             progressive multifocal leukoencephalopathy, lymphoma, or malignancy requiring systemic&#xD;
             therapy&#xD;
&#xD;
          -  Prior exposure (&gt; 7 days) to tipranavir&#xD;
&#xD;
          -  History of clinically significant nervous system or muscle diseases, seizure disorder,&#xD;
             or psychiatric disorder that might impair adherence to the protocol&#xD;
&#xD;
          -  Taking of any known P450 3A enzyme-inducing drugs within 30 days of study entry and&#xD;
             including the following: rifabutin, rifampin, carbamazepine, dexamethasone,&#xD;
             phenobarbital, phenytoin, sulfadimidine, sulfinpyrazone, or troleandomycin&#xD;
&#xD;
          -  Hypersensitivity to tipranavir and/or ritonavir&#xD;
&#xD;
          -  Use of interferons, interleukins, HIV vaccines, or any active immunizations within 30&#xD;
             days prior to study entry&#xD;
&#xD;
          -  Taking of any investigational medication with the exception of adefovir dipivoxil&#xD;
             (Preveon™) and amprenavir (Agenerase™) within 30 days of study entry&#xD;
&#xD;
          -  Pregnancy or lactation (serum β-human chorionic gonadotrophin test had to have been&#xD;
             negative within 14 days of study entry)&#xD;
&#xD;
          -  Evidence of active substance abuse, which in the investigator's opinion, could affect&#xD;
             compliance to the protocol&#xD;
&#xD;
          -  In the investigator's judgment, inability to comply with the protocol requirements for&#xD;
             reasons other than those specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>September 11, 2014</study_first_submitted>
  <study_first_submitted_qc>September 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

